ObsEva SA to present at ESHRE Virtual 36th Annual Meeting, July 5-8, 2020

Rhea-AI Summary

ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company focused on women's reproductive health, announced its participation in the ESHRE Virtual 36th Annual Meeting from July 5-8, 2020. Dr. Hugh Taylor will present on July 6th about the efficacy and safety of linzagolix for heavy menstrual bleeding related to uterine fibroids. Dr. Oliver Pohl will present on July 7th regarding the action of oxytocin receptor antagonists in assisted reproductive technology. Both presentations will be accessible via ObsEva's website.

 

Geneva, Switzerland and Boston, MA – July 3, 2020 – ObsEva SA (NASDAQ: OBSV), a clinical-stage biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health, today announced that they will present at ESHRE Virtual 36^th Annual Meeting, taking place July  5-8, 2020.

 

Dr Hugh Taylor, to present on Monday, July 6th, from 11:00 - 11:10 CEST in Session 05

Presentation number: O-190 (pre-selected for Clinical Science Award for Oral Presentation and for the Fertility Society of Australia Exchange Award)

Efficacy and safety of linzagolix on heavy menstrual bleeding (HMB) due to uterine fibroids (UF): Results from a placebo-controlled, randomized, Phase 3 trial

 

Dr Oliver Pohl, to present on Tuesday, July 7th, from 15:25 - 15:35 CEST in Session 48

Presentation number: O-027 

The mechanism of action of oxytocin receptor antagonists (OTRan) in ART – a study of nolasiban on biomarkers of uterine receptivity in healthy female volunteers

 

The link for both presentations on the ESHRE platform, will be available under “Events Calendar” in the investors section of ObsEva’s website at www.ObsEva.com

 

About ObsEva

ObsEva is a biopharmaceutical company developing and commercializing novel therapies to improve women’s reproductive health and pregnancy. Through strategic in-licensing and disciplined drug development, ObsEva has established a late-stage clinical pipeline with development programs focused on treating endometriosis, uterine fibroids, preterm labor, and improving ET outcomes following IVF. ObsEva is listed on the Nasdaq Global Select Market and is trading under the ticker symbol "OBSV" and on the SIX Swiss Exchange where it is trading under the ticker symbol “OBSN”. For more information, please visit www.ObsEva.com.

 

For further information, please contact:

 

CEO Office contact
Shauna Dillon
Shauna.dillon@obseva.ch
+41 22 552 1550

Investor Contact
Mario Corso
Vice President, Investor Relations
mario.corso@obseva.com

+1 857 972 9347 Office
+1 781 366 5726 Mobile

 

Attachment

• Press Release in Pdf

FAQ

What is ObsEva presenting at the ESHRE Virtual Annual Meeting?

ObsEva will present research on linzagolix for heavy menstrual bleeding and oxytocin receptor antagonists at the ESHRE Virtual 36th Annual Meeting.

When are the ObsEva presentations scheduled during the ESHRE meeting?

Dr. Hugh Taylor's presentation is on July 6th at 11:00 CEST, and Dr. Oliver Pohl's presentation is on July 7th at 15:25 CEST.

What is the main topic of Dr. Taylor's presentation?

Dr. Taylor's presentation focuses on the efficacy and safety of linzagolix for heavy menstrual bleeding due to uterine fibroids.

What will Dr. Pohl discuss in his presentation?

Dr. Pohl will discuss the mechanism of action of oxytocin receptor antagonists in assisted reproductive technology.

Where can I find the presentations by ObsEva?

Links to both presentations will be available under the 'Events Calendar' section on ObsEva's website.

What is the stock symbol for ObsEva?

ObsEva is traded on NASDAQ under the stock symbol 'OBSV'.